Cholinesterase (ChE), divided into two enzymes acetylcholinesterase (AChE) and butyrylcholinestarase (BChE), have been identified as potential targets in the treatment of AD, myasthenia gravis and glaucoma. This evidence concerns the gene ACHE and Alzheimer disease.